CUPERTINO, Calif., Feb. 7, 2024
/PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced
that James E. Brown, President and
Chief Executive Officer, will present at the Oppenheimer 34th
Annual Healthcare Life Sciences Conference, to be held virtually,
February 13-14, 2024.
Presentation details are as follows:
Date and
Time:
|
Wednesday, February 14,
10:40 a.m. ET
|
Webcast:
|
https://wsw.com/webcast/oppenheimer33/drrx/2815552
|
A link to the webcast will also be available by
accessing DURECT's homepage at www.durect.com and
clicking on the "Events" page under the "Investors" section.
Management will be available for one-on-one meetings with
institutional investors during the conference. Please contact your
Oppenheimer representatives or DURECT directly.
About DURECT Corporation
DURECT is a late-stage
biopharmaceutical company pioneering the development of epigenetic
therapies that target dysregulated DNA methylation to transform the
treatment of serious and life-threatening conditions, including
acute organ injury and cancer. Larsucosterol, DURECT's lead drug
candidate, binds to and inhibits the activity of DNA
methyltransferases (DNMTs), epigenetic enzymes that are elevated
and associated with hypermethylation found in alcohol-associated
hepatitis (AH) patients. Larsucosterol is in clinical development
for the potential treatment of AH, for which the U.S. Food and Drug
Administration (FDA) has granted a Fast Track Designation. In
addition, POSIMIR® (bupivacaine solution) for
infiltration use, a non-opioid analgesic utilizing the innovative
SABER® platform technology, is FDA-approved and is
exclusively licensed to Innocoll Pharmaceuticals for sale and
distribution in the United
States. For more information about DURECT, please visit
www.durect.com and follow us on X (formerly Twitter) at
https://x.com/DURECTCorp.
DURECT Forward-Looking Statements
This press
release contains forward-looking statements, including statements
made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995, relating to: the
potential for larsucosterol to treat patients with AH, the
potential FDA or other regulatory approval of larsucosterol for the
treatment of AH, the commercialization of POSIMIR by Innocoll, and
the potential to develop larsucosterol for AH. Actual results may
differ materially from those contained in the forward-looking
statements contained in this press release, and reported results
should not be considered as an indication of future performance.
The potential risks and uncertainties that could cause actual
results to differ from those projected include, among other things,
the risk that future clinical trials of larsucosterol do not
confirm the results from subset analyses of the AHFIRM trial,
including geographic or other segmentation, or of earlier clinical
or pre-clinical trials, or do not demonstrate the safety or
efficacy of larsucosterol in a statistically significant manner,
the risk that the FDA or other government agencies may require
additional clinical trials for larsucosterol before approving it
for the treatment of AH, risks that Innocoll may not commercialize
POSIMIR successfully, and risks related to the sufficiency of our
cash resources, our anticipated capital requirements and capital
expenditures, our need or desire for additional financing, our
ability to meet the minimum bid price for continued listing on
Nasdaq, our ability to obtain capital to fund our operations and
expenses and our ability to continue to operate as a going concern.
Further information regarding these and other risks is included in
DURECT's most recent U.S. Securities and Exchange Commission (SEC)
filings, including its Annual Report on Form 10-K for the year
ended December 31, 2022 and Quarterly
Report on Form 10-Q for the quarter ended September 30, 2023, under the heading "Risk
Factors." These reports are available for free on our website
at www.durect.com under the "Investors" tab and on the
SEC's website at www.sec.gov. All information provided in this
press release is based on information available to DURECT as of the
date hereof, and DURECT assumes no obligation to update this
information as a result of future events or developments, except as
required by law.
NOTE: POSIMIR® is a trademark of Innocoll
Pharmaceuticals, Ltd. in the U.S. and a trademark of DURECT
Corporation outside of the U.S. SABER® is a trademark of
DURECT Corporation. Other referenced trademarks belong to their
respective owners. Larsucosterol is an investigational drug
candidate under development and has not been approved for
commercialization by the FDA or other health authorities for any
indication.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/durect-corporation-to-present-at-the-oppenheimer-34th-annual-healthcare-life-sciences-conference-302056826.html
SOURCE DURECT Corporation